文献速递血管炎

阿巴西普治疗巨细胞动脉炎的随机双盲试验

A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.
PubMed 文献 · Arthritis Rheumatol · 2017-03-03

这项多中心随机双盲试验纳入49例新诊断或复发性巨细胞动脉炎患者,先接受阿巴西普10 mg/kg静脉给药联合每日泼尼松治疗,第12周达缓解者随机继续阿巴西普或换用安慰剂,泼尼松按标准化方案减量至第28周停用。12个月无复发生存率阿巴西普组48%对安慰剂组31%(P=0.049),中位缓解持续时间9.9个月对3.9个月(P=0.023),不良事件频率与严重程度两组无差异。

要点

  • 阿巴西普联合泼尼松可提高GCA患者12个月无复发生存率(48%对31%,P=0.049)。
  • 阿巴西普组中位缓解持续时间更长(9.9个月对3.9个月,P=0.023)。
  • 两组不良事件包括感染的频率与严重程度无差异。

核心结论

  • 在GCA患者中,泼尼松方案加用阿巴西普可降低复发风险,且与单用泼尼松相比未增加毒性。

研究设计与样本

  • 多中心随机双盲试验,49例新诊断或复发性GCA患者先接受阿巴西普10 mg/kg静脉给药(第1、15、29天及第8周)联合每日泼尼松治疗。
  • 第12周达缓解的41例患者双盲随机继续每月阿巴西普或换用安慰剂,两组均按标准化方案减量泼尼松并于第28周停用。

主要发现

  • 12个月无复发生存率阿巴西普组48%,安慰剂组31%(P=0.049)。
  • 中位缓解持续时间阿巴西普组9.9个月,安慰剂组3.9个月(P=0.023)。
  • 两组不良事件包括感染的频率与严重程度无差异。

关键数值与推荐

  • 主要终点为缓解持续时间(无复发生存率)。
  • 泼尼松标准化减量至第12周每日20 mg,第28周全部停用。

临床怎么用

  • 对GCA患者,在泼尼松标准化减量方案基础上加用阿巴西普可能降低复发风险且不增加毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA). METHODS: In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double-blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse-free survival rate). RESULTS: Forty-nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; of these, 41 reached the week 12 randomization and underwent a blinded randomization to receive abatacept or placebo. Prednisone was tapered using a standardized schedule, reaching a daily dosage of 20 mg at week 12 with discontinuation in all patients at week 28. The relapse-free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (P = 0.049). A longer median duration of remission was seen in those receiving abatacept compared to those receiving placebo (median duration 9.9 months versus 3.9 months; P = 0.023). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms. CONCLUSION: In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Langford CA, Cuthbertson D, Ytterberg SR, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol. 2017. PMID: 28133925. doi:10.1002/art.40044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。